Cargando…
Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease
Despite the promising effectiveness of the coronavirus disease 2019 vaccination using an mRNA vaccine, the short efficacy duration and some poor responses to the vaccination remain major concerns. We aimed to clarify the monthly kinetics of the anti-SARS-CoV-2 spike receptor-binding domain antibody...
Autores principales: | Sugiura, Tomoko, Sugiura, Hiroaki, Kato, Hiroaki, Nariai, Yuko, Mizumoto, Yuuki, Hanada, Kozue, Takahashi, Rieko, Hinotubo, Yukari, Tanaka, Naoko, Sasaki, Mutsumi, Eguchi, Haruki, Kamino, Hiroki, Urano, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844396/ https://www.ncbi.nlm.nih.gov/pubmed/36648857 http://dx.doi.org/10.3390/idr15010003 |
Ejemplares similares
-
Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals
por: Maeda, Kenji, et al.
Publicado: (2021) -
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
por: Maeda, Kenji, et al.
Publicado: (2021) -
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023) -
Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
por: Yamamoto, Shohei, et al.
Publicado: (2023) -
SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study
por: Takeuchi, Junko S., et al.
Publicado: (2022)